Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer

Current targeted therapies using small kinase inhibitors and antibodies have limited efficacy in treating prostate cancer (PCa), a leading cause of cancer death in American men. We have developed a novel strategy by engineering an RNA-based aptamer-siRNA chimera, in which a bivalent aptamer specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hong Yan, Yu, Xiaolin, Liu, Haitao, Wu, Daqing, She, Jin-Xiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960556/
https://www.ncbi.nlm.nih.gov/pubmed/27456457
http://dx.doi.org/10.1038/srep30346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960556/
https://www.ncbi.nlm.nih.gov/pubmed/27456457
http://dx.doi.org/10.1038/srep30346

Ejemplares similares